Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

FAANG Induced Blue Sky Produces New Record High’s On Monday- GME Seeks $1B

By John F. Heerdink, Jr.


QUOTE OF THE DAY – “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel

Happy Monday!

I hope that all of you had a wonderful holiday weekend and that Monday’s markets treated you well. 

Broadly, it was a significantly green day that was led by the superior performances of the communication services and consumer discretionary sectors which were both up +2.3%. They were also closely followed by the information technology sector that moved up 2% as well. With that the highly weighted and highly influential FAANG stocks once again moved influentially higher and ended as follows: Apple (AAPL) shares closed at $125.90, +.2.36%, Amazon (AMZN) closed at $3,226.73, +2.08%, & Alphabet (GOOG) closed at $2,225.55, jumping an amazing+4.11% after it was confirmed that the Supreme Court had ruled in their favor regarding a copyright issue with Oracle (ORCL), Facebook (FB)also  closed at $308.916, +3.43 after establishing a new 52-wk high  of $310.76% & Netflix (NFLX) closed at $540.67/share, +.23%. It definitely paid to be invested in the FAANG’s again today.

Not a FAANG, but might as well be added to the list, is the ever so popular and thought provoking EV giant and Elon Musk led Tesla (TSLA) which closed higher today at $691.05, up 4.43%. TSLA recently reporting that in the first quarter that they had produced just over 180,000 vehicles and delivered nearly 185,000 vehicles. They also stated that they are encouraged by the strong reception of the Model Y in China and are quickly progressing to full production capacity. The new Model S and Model X have also been exceptionally well received, with the new equipment installed and tested in Q1 and they are reportedly in the early stages of ramping production. Maybe the acronym should be changed to “FAANGT” or “TFAANG”. I am open to suggestions…

Getting back to the board market story, all indices indeed closed higher today with the Dow 33,527.19 (+1.13%) and the S&P 500 4,077.91 (+1.44%) establishing new record highs and the Nasdaq closed at 13,480.11 (+1.76%), which now has its eye on the 14k level. The smalls on the Russell 2000 also continued to move higher closing at 2,264.89 (+.49%).

The macroeconomic schedule continued to deliver a significant push for the broad markets. On Friday, we received the March nonfarm payrolls which showed a rise by 916k while private sector payrolls rose by 780k & the unemployment rate was 6% in March. Today, the ISM Non-Manufacturing Index report showed an rise to 63.7% in March. This is the highest reading on record. 

The 10-yr yield moved up 1 basis point closing at 1.72%, while the 2-yr yield closed flat at .18% & the U.S. Dollar Index pulled back .5% closing at 92.60.

Oil prices pulled back 4.4% to close at $58.69/bbl while the energy sector fell 2.4% & was the only sector to end in the red today. 

The iShares Nasdaq Biotechnology ETF (IBB) edged higher closing at 152.17, +.43%, while the NYSE ARCA Biotech Index (^BTK) closed at 5,601.33, +.53% .

The iShares Silver Trust ETF (SLV) closed at $23.09, -.26% & the SPDR Gold Shares (GLD) closed at $161.92, -.04%. Silver prices closed at $24.872/oz, -.15. Gold prices closed at 1,729, -$3.

$1 BILLION OFFERING FOR GME? GameStop Corp. (NYSE: GME) ($186.95, -2.35%) today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission, under which it may offer and sell up to a maximum of 3,500,000 shares of its common stock  from time to time through an “at-the-market” equity offering program . The Company intends to use the net proceeds from any sales of its Common Stock under the ATM Offering to further accelerate its transformation as well as for general corporate purposes and further strengthening its balance sheet. The timing and amount of any sales will be determined by a variety of factors considered by the Company. Common Stock will be offered through Jefferies LLC , which is serving as the sales agent. Jefferies may sell Common Stock by any lawful method deemed to be an “at-the-market offering” defined by Rule 415(a)(4) of the Securities Act of 1933, as amended, including without limitation, sales on any existing trading market. Sales may be made at market prices prevailing at the time of a sale or at prices related to prevailing market prices. As a result, sales prices may vary. They also stated that we should please note that their press release wasfor informational purposes only and it does not represent an offer to sell or the solicitation of an offer to buy any of the Company’s Common Stock & in no event will the Company sell more than 3,500,000 shares of Common Stock under the ATM Offering, and aggregate gross proceeds will not exceed $1,000,000,000.

VP WATCHLIST HIGHLIGHTS


You can review our complete VP Watchlist that we believe deserve consideration for short term and long term portfolio adds that include Apple, Tesla, & seven other names. The pages will enable you to stay informed and learn more about these companies daily.

Please review few of the updates on a few of the VP Watchlist companies below: 



  • Shares of next generation of gene silencing therapy firm NeuBase Therapeutics (NBSE) closed trading at $7.34, +.27%. Recently, Neubase reported its financial results for the three-month period ended December 31, 2020. Review the story here.
    • After the close today, NBSE filed a $250,000,000 missed shelf in the aggregate of any combination of the securities identified above from time to time in one or more offerings, either individually or in combination with other securities. We may also offer common stock or preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants.
    • Oppenheimer’s analyst Hartaj Singh recently reiterated his OUTPERFORM Rating and his Price Target of $17. 
    • Recently, NeuBase announced the execution of a binding agreement to acquire infrastructure, programs and intellectual property for several peptide-nucleic acid (PNA) scaffolds from Vera Therapeutics, formerly known as TruCode Gene Repair, Inc. The technology has demonstrated the ability to resolve disease in genetic models of several human indications. The acquisition was reported to bolster NeuBase’s capabilities and reinforces the Company’s position as a leader in the field of genetic medicine. Read the complete story. 
    • NeuBase is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.
    • We expect to see the company to announce an update on its work in Huntington’s Disease and also sign a corporate deal of some kind in and around the April 2021 timeframe based on recent conversations & expectations of management.


  • Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $83.66/share, +2.14%.

    • On March 25, FATE announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 years with the Company. Dr. Shoemaker has been with Fate Therapeutics since February 2009, having served as the Company’s Chief Scientific Officer since May 2015. Bob Valamehr, Ph.D., Chief Research and Development Officer of Fate Therapeutics and scientific leader of its iPSC Product Platform since January 2010, will continue to lead all research and development activities.
    • On Dec. 6, 2020, Fate presented a patient case study from the Company’s Phase 1 clinical trial of FT596, its universal, off-the-shelf, CD19-targeted chimeric antigen receptor (CAR) natural killer (NK) cell product candidate, at the 62nd Annual Society of Hematology Annual Meeting and Exposition and the street loved it. NK cells are the body’s first line of defense against viral infections and cancerous cells with an innate ability to rapidly seek and destroy transformed cells. NK cell therapy has the potential to 1) target multiple pathogenic antigens with measurably more efficient cytotoxicity, 2) be better controlled to reduce risk of cytokine storms and 3) be produced from a variety of sources without relying on patient-specific immune cells. Dr. Wayne Chu, Senior Vice President, Clinical Development of Fate Therapeutics stated, “The safety, pharmacokinetics and clinical activity observed following both the first and second single-dose treatment cycles of FT596 are compelling, especially when considering that the administered cell dose was significantly lower than the recommended cell dose of FDA-approved autologous CD19-targeted CAR T-cell therapies and that the heavily pre-treated patient was refractory to last prior therapy. We are excited the CAR component of FT596 has shown clinical activity at this low dose level, and we continue to enroll patients in dose escalation with FT596 as a monotherapy and in combination with rituximab.”


  • INVO Bioscience (NASDAQ: INVO) is a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System. Shares INVO closed at $4.29/share, -4.03%.
    • After the close March 30, INVO announced 2020 financial results and highlights.  Steve Shum, Chief Executive Officer of INVO Bioscience stated, “In the face of a difficult year for many industries, including the fertility business, I am extremely proud of the accomplishments of the entire INVO Bioscience team. During the year, we put in place a number of building blocks for the future, which are already beginning to pay dividends. Recently we announced our plan to open our first U.S.-based INVOcell clinic in partnership with some of the most highly accomplished INVOcell practitioners in the world. Our partners are not only extremely well-versed in the INVOcell technology, but also have a proven track record of successful implementation of the platform within an established clinical setting. A few months prior, we announced that we plan to open dedicated INVOcell clinics in Mexico with Dr. Francisco Arredondo and Dr. Ramiro Ramirez, who were also early adopters of the INVOcell solution and have established a successful track record of successful implementation of INVOcell in a clinical setting. We believe the combination of strong distribution partners such as Ferring in the U.S. and other locations around the world, coupled with dedicated INVOcell clinics partnerships which INVO Bioscience has an equity interest in, position the Company well for the future. Another key development during the year was the availability of additional positive real-world usage data highlighting the success of INVOcell, including a published peer-reviewed manuscript (report). We expect to see further data from this year’s SART information in the near future. In our opinion, this expanded retrospective, real world validated data is extremely valuable to our commercial efforts and builds confidence with practitioners. We believe that this expanding portfolio of usage data will play an important role in expanding and accelerating market adoption.”
    • INVO’s Management Issued a letter to shareholders on Jan. 7 that spoke to their key developments and future initiatives that have positioned their product INVOcell® within the severely underserved fertility market. PLEASE read the story here.

    • On March 8, INVO announced that they has agreed to an amendment of their agreement with Ferring Pharmaceuticals that provides for an increase in the number of INVO company-owned US-based clinics initially allowable under the agreement and removes certain geographical restrictions. The amendment also adjusted the remaining annual 2020 minimum contractual product purchase requirement, whereby Ferring will place a $501,000 order, which will be recognized as revenue by INVO Bioscience in the first quarter of 2021. READ STORY.
    • On March 1, INVO announced the Company has received approval by COFEPRIS to import INVOcell into Mexico. In late 2020, INVO Bioscience established a joint venture focused on establishing fertility centers dedicated to offering INVOcell, with the initial center, called Positib Fertility, to be located in the city of Monterrey, Mexico. Steve Shum, CEO of INVO Bioscience, commented, “We are extremely pleased to have received approval by COFEPRIS to begin importing INVOcell into Mexico. This was a key step in the process to open our first joint venture owned clinic in the large and growing Mexico market for infertility services. Our internal team along with our JV partners have and continue to work aggressively and with a relentless focus to bring the INVOcell treatment option to the many patients in need of care within Mexico.”
    • On Jan. 27, INVO announced that it has advanced its commercialization efforts into the European fertility market by securing initial orders of INVOcell in Madrid and Barcelona, Spain. INVOcell will initially be available at three separate existing fertility clinics which have placed orders and commenced training. Please read the story here.
    • Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity.
    • Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.


  • Shares of Chinook Therapeutics (KDNY), a clinical-stage biotechnology company developing precision medicines for kidney diseases, closed today at $15.27, -1.48%.
    • On Monday, April 5th, KDNY announced a transaction with Van Herk Investments, a leading European life science investor, to create and fund a new company called Sairopa, with a pipeline focused on research and development of non-renal monoclonal antibodies generated through Aduro Biotech’s B-Select platform. Chinook will own approximately 40 percent of Sairopa after the first tranche of financing from Van Herk and have one seat on Sairopa’s Board of Directors.
    • On Tuesday, March 30, Chinook announced their upcoming data presentations at the ISN World Congress of Nephrology 2021 from April 15 – 19, 2021 and the 58th ERA-EDTA Congress from June 5 – 8, 2021.
    • On March 16, Chinook announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the ALIGN Study, a pivotal phase 3 clinical trial evaluating the efficacy and safety of atrasentan, a potent and selective inhibitor of the endothelin A receptor. “The initiation of the phase 3 ALIGN Study is an important milestone for Chinook as we advance our pipeline of programs for rare, severe chronic kidney diseases,” said Alan Glicklich, M.D., chief medical officer of Chinook. “Atrasentan has been studied in over 5,300 diabetic kidney disease patients in the phase 2 RADAR and phase 3 SONAR studies, demonstrating rapid, sustained proteinuria reductions of approximately 30 to 35 percent as well as improved eGFR. Importantly, treatment with atrasentan also resulted in a reduction in clinical outcomes of development of end-stage kidney disease and doubling of serum creatinine. We look forward to exploring the proteinuria-lowering, anti-inflammatory and anti-fibrotic effects of atrasentan in patients with IgA nephropathy, a serious progressive disease for which there are no approved therapies.”

    • On March 1, Chinook and Evotec SE announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases. Based on Evotec’s proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterize and validate novel mechanisms and discover precision medicines for PKD, lupus nephritis, IgA nephropathy and other primary glomerular diseases. The collaboration will also involve further characterization of pathways and patient stratification strategies for programs currently in Chinook’s clinical and preclinical pipeline. “We are excited to embark on this strategic collaboration with Evotec, the leading drug discovery alliance and development partner in nephrology,” said Andrew King, D.V.M., Ph.D., Head of Renal Discovery and Translational Medicine at Chinook. “Gaining access to the NURTuRE cohort study and other proprietary patient biobanks, along with Evotec’s multi-omics integration platform, will enable us to define the molecular drivers of kidney diseases, identify novel targets for drug development in selected patient sub-populations and continue to build the foundation for our precision medicine approach. With a focus on comprehensive molecular disease classification, combined with prospective clinical outcomes, Chinook has the opportunity to potentially deliver targeted therapies to the right patient populations.”
    • On Feb. 2nd, Chinook announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A (LDHA) for primary hyperoxaluria (PH). PH is a group (PH1, PH2 and PH3) of ultra-rare genetic diseases caused by enzyme mutations that result in excess oxalate production in the liver, and in its most severe forms, can lead to end-stage kidney disease at a young age. Inhibition of LDHA with CHK-336 allows for the potential to treat all forms of PH and other disorders arising from excess oxalate, while its liver-targeted tissue distribution profile enables maximal inhibition of liver oxalate production with minimal systemic exposure. Please read the story here.
  •  


  • Shares of Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at $2.16, +2.37%.
    • Today, March 31, Atossa announced their financial results for the fiscal year ended December 31, 2020, and provided an update on recent company developments. Read the complete story. 
    • On Monday, March 22, Atossa  announced that it had entered into a securities purchase agreement with institutional investors to purchase $50 million of its shares of common stock and warrants in a registered direct offering priced at-the-market under Nasdaq rules. Read the complete story.  Atossa has now raised ~$141M in gross proceeds (via registered directs and warrant exercises) since Dec. 2020 affording the company a significant development runway and many more options to be considering including acquisitions. 
    • On March 11, Atossa announced the FDA has issued a “Safe to Proceed” letter under their Expanded Access Pathway, permitting the use of Atossa’s oral Endoxifen as a treatment in an ovarian cancer patient. The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief. Under the FDA expanded access program, the use of Atossa’s proprietary oral Endoxifen is restricted solely to this patient. Approval from the Institutional Review Board (IRB) must be obtained prior to providing oral Endoxifen to this patient. Read the complete story.
    • On Feb. 25, Atossa announced final results from its Phase 1 double-blinded, randomized, placebo-controlled clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. AT-301 was considered to be safe and well tolerated in healthy male and female participants in this study at two different dose levels over 14 days. AT-301 is being developed for at home use for patients recently diagnosed with COVID-19. There are currently no FDA-approved therapies to treat COVID-19 at home. Steven Quay, M.D., Ph.D., Atossa’s President and CEO stated, “The results from this study are very encouraging and we look forward to quickly commencing the next study of AT-301. We recently received input from the FDA on this program and based in part on that input, we are now preparing to conduct an additional pre-clinical study, which we expect to start this quarter. Following that, we expect to apply to the FDA to commence a Phase 2 study here in the United States.”
    • Early in February, Atossa’s President and CEO Dr. Steven C. Quay issued his annual Letter to Stockholders highlighting key accomplishments and strategy for 2021. Please review it here.
  •  


Markets

Symbol Name Last Price Change % Change

Big Movers

Symbol Name Last Price Change % Change

Bond Markets & US Dollar

Symbol Name Last Price Change % Change

Economic Reports

  • On Monday, the macroeconomic schedule delivered the ISM Non-Manufacturing Index report which showed a rise to 63.7% in March.

Agriculture & Energy

Symbol Name Last Price Change % Change

Biotech & Healthcare

Symbol Name Last Price Change % Change

Consumer Goods & Trends

Symbol Name Last Price Change % Change

Financials & Fintech

Symbol Name Last Price Change % Change

Materials & Natural Resources

Symbol Name Last Price Change % Change

Technology & Beyond

Symbol Name Last Price Change % Change

Investing & Inspiration

  1. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel
  2. “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  3. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  4. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

  5. “Never depend on a single income, make an investment to create a second source.” Warren Buffet

  6. Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
    ― Warren Buffett
  7. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  8. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  9. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  10. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  11. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  12. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  13. The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  14. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  15. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  16. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  17. “No Price is too low for a bear or too high for a bull.” — Anonymous
  18. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  19. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  20. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  21. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  22. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  23. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  24. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  25. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  26. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  27. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  28. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  29. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  30. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  31. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  32. “Know what you own, and know why you own it.” – Peter Lynch
  33. “Liquidity is only there when you don’t need it.” -Old Proverb
  34. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  35. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  36. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  37. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  38. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  39. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  40. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  41. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  42. I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  43. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  44. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  45. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  46. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  47. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  48. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  49. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  50. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  51. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  52. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  53. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  54. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  55. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger
Symbol Name Last Price Change % Change

Videos

Please consider viewing these interesting videos: